PMID- 37201063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230521
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 14
IP  - 2
DP  - 2023 Apr 29
TI  - Effect of negative emotions on patients with advanced gastric cancer receiving 
      systemic chemotherapy: a prospective study.
PG  - 952-962
LID - 10.21037/jgo-23-248 [doi]
AB  - BACKGROUND: Most patients with advanced gastric cancer (GC) are treated with 
      systemic chemotherapy and many factors have remarkable impacts on their 
      prognosis. However, the importance of psychological status in the prognosis of 
      advanced GC patients is still unclear. This prospective study was performed to 
      analyze the impact of negative emotions on GC patients treated with systemic 
      chemotherapy. METHODS: Advanced GC patients admitted to our hospital between 
      January 2017 and March 2019 were prospectively enrolled. Demographic and clinical 
      data were collected, as were any adverse events (AEs) related to systemic 
      chemotherapy. Self-rating anxiety scale (SAS) and self-rating depression scale 
      (SDS) were used to assess negative emotions. The primary outcome was 
      progression-free survival (PFS) and overall survival (OS), and the secondary 
      outcome was the quality of life which was assessed by The European Organization 
      for Research and Treatment of Quality of Life Questionnaire-Core 30. Cox 
      proportional hazards models were used to analyze the effects of negative emotions 
      on prognosis, and logistic regression models were used to analyze the risk 
      factors related to negative emotions. RESULTS: A total of 178 advanced GC 
      patients were enrolled in this study. A total of 83 patients were divided into a 
      negative emotion group and 95 patients were divided into normal emotion group. 72 
      patients experienced AEs during treatment. Many more patients experienced AEs in 
      the negative emotion group than in the normal emotion group (62.7% vs. 21.1%, 
      P<0.001). Enrolled patients were followed up for at least 3 years. It was found 
      both PFS and OS were much lower in the negative emotion group than in the normal 
      emotion group (P=0.0186 and 0.0387, respectively). Participants in negative 
      emotion group had lower health status and more severe symptoms. Negative 
      emotions, lower body mass index (BMI), and IV tumor stage were identified as risk 
      factors. In addition, higher BMI and marital status were identified as protective 
      factors of negative emotions. CONCLUSIONS: Negative emotions have a significant 
      adverse effect on the prognosis of GC patients. The main risk factor of negative 
      emotions is AEs during treatment. It is necessary to closely monitor the 
      treatment process and improve the psychological status of patients.
CI  - 2023 Journal of Gastrointestinal Oncology. All rights reserved.
FAU - Tao, Fengyan
AU  - Tao F
AD  - Nangtong Health College of Jiangsu Province, Nantong, China.
FAU - Gong, Lili
AU  - Gong L
AD  - Nangtong Health College of Jiangsu Province, Nantong, China.
FAU - Dong, Qing
AU  - Dong Q
AD  - Department of Chemotherapy, the Affiliated Hospital of Nantong University, 
      Nantong, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC10186533
OTO - NOTNLM
OT  - Negative emotions
OT  - advanced gastric cancer (GC)
OT  - prospective study
OT  - systemic chemotherapy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jgo.amegroups.com/article/view/10.21037/jgo-23-248/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/05/18 19:12
MHDA- 2023/05/18 19:13
PMCR- 2023/04/29
CRDT- 2023/05/18 16:54
PHST- 2023/02/15 00:00 [received]
PHST- 2023/04/20 00:00 [accepted]
PHST- 2023/05/18 19:13 [medline]
PHST- 2023/05/18 19:12 [pubmed]
PHST- 2023/05/18 16:54 [entrez]
PHST- 2023/04/29 00:00 [pmc-release]
AID - jgo-14-02-952 [pii]
AID - 10.21037/jgo-23-248 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2023 Apr 29;14(2):952-962. doi: 10.21037/jgo-23-248.